Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

Figures & data

Table 1. Characteristics of the studied patient groups.

	Patients without TD (n = 328)	Patients with TD (n = 121)	P value
Gender: Male, n (%)	152 (46.3%)	71 (58.7%)	0.027
Female, n (%)	176 (53.7%)	50 (41.3%)
Age, years	37 [31; 48]	48 [37.5; 58]	<0.001
Age of onset, years	24 [20; 30]	25 [20; 32]	0.974
Duration of disease, years	11 [5; 18]	20 [12; 29.5]	<0.001
CPZeq	396 [200; 750]	500 [286.2; 750]	0.021

Table 2. Genotype distribution in patients with TD.

Gene	Polymorphic variant	Genotypes/Alleles	With TD	Without TD	OR		χ^2	P
					value	95% CI
CHRM1	rs2075748	GG	80 (66.7%)	223 (68.4%)	0.92	0.59–1.44	0.179	0.915
		GA	36 (30.0%)	94 (28.8%)	1.06	0.67–1.67
		AA	4 (3.3%)	9 (2.8%)	1.21	0.37–4.02
		G	0.817	0.828	0.92	0.63–1.36	0.16	0.69
		A	0.183	0.172	1.08	0.74–1.59
	rs2067479	TT	0 (0.0%)	0 (0.0%)	2.7	0.05–136.61	1.311	0.252
		TC	7 (5.8%)	32 (9.8%)	0.57	0.24–1.32
		CC	114 (94.2%)	295 (90.2%)	1.77	0.76–4.12
		T	0.029	0.049	0.58	0.25–1.33	1.7	0.19
		C	0.971	0.951	1.73	0.75–3.97
	rs542269	CC	5 (4.5%)	14 (4.6%)	0.97	0.34–2.77	1.07	0.586
		CT	39 (35.1%)	123 (40.6%)	0.79	0.50–1.25
		TT	67 (60.4%)	166 (54.8%)	1.26	0.81–1.96
		C	0.221	0.249	0.85	0.59–1.23	0.72	0.4
		T	0.779	0.751	1.17	0.81–1.69
CHRM2	rs2061174	TT	60 (49.6%)	144 (44.0%)	1.25	0.82–1.90	5.633	0.06
		TC	53 (43.8%)	134 (41.0%)	1.12	0.74–1.71
		CC	8 (6.6%)	49 (15.0%)	0.4	0.18–0.88
		T	0.715	0.645	1.38	1.00–1.90	3.84	0.05
		C	0.285	0.355	0.73	0.53–1.00
	rs324650	AA	27 (22.5%)	79 (24.2%)	0.91	0.55–1.49	0.171	0.918
		AT	59 (49.2%)	159 (48.8%)	1.02	0.67–1.54
		TT	34 (28.3%)	88 (27.0%)	1.07	0.67–1.70
		A	0.471	0.486	0.94	0.70–1.26	0.17	0.68
		T	0.529	0.514	1.06	0.79–1.43
	rs2350780	AA	53 (43.8%)	142 (43.4%)	1.02	0.67–1.55	1.467	0.48
		AG	56 (46.3%)	139 (42.5%)	1.17	0.77–1.77
		GG	12 (9.9%)	46 (14.1%)	0.67	0.34–1.32
		A	0.669	0.647	1.11	0.81–1.51	0.4	0.53
		G	0.331	0.353	0.9	0.66–1.24
	rs1824024	GG	8 (6.7%)	49 (15.0%)	0.4	0.19–0.88	6.035	0.049
		GT	55 (45.8%)	125 (38.3%)	1.36	0.89–2.08
		TT	57 (47.5%)	152 (46.6%)	1.04	0.68–1.58
		G	0.296	0.342	0.81	0.59–1.11	1.69	0.19
		T	0.704	0.658	1.24	0.90–1.71
	rs7810473	AA	44 (37.6%)	99 (35.0%)	1.12	0.72–1.75	0.292	0.864
		AG	51 (43.6%)	131 (46.3%)	0.9	0.58–1.38
		GG	22 (18.8%)	53 (18.7%)	1	0.58–1.74
		A	0.594	0.581	1.05	0.77–1.44	0.11	0.74
		G	0.406	0.419	0.95	0.70–1.29
	rs2350786	GG	60 (54.5%)	155 (51.2%)	1.15	0.74–1.78	1.198	0.549
		GA	44 (40.0%)	122 (40.3%)	0.99	0.63–1.54
		AA	6 (5.5%)	26 (8.6%)	0.61	0.25–1.54
		G	0.745	0.713	1.18	0.83–1.68	0.85	0.36
		A	0.255	0.287	0.85	0.60–1.20
	rs324640	GG	37 (30.8%)	103 (31.5%)	0.97	0.62–1.52	0.038	0.981
		GA	56 (46.7%)	153 (46.8%)	1	0.65–1.51
		AA	27 (22.5%)	71 (21.7%)	1.05	0.63–1.73
		G	0.542	0.549	0.97	0.72–1.31	0.04	0.85
		A	0.458	0.451	1.03	0.77–1.39
	rs1378650	CC	33 (29.5%)	76 (25.0%)	1.25	0.77–2.03	1.933	0.38
		CT	50 (44.6%)	159 (52.3%)	0.74	0.48–1.14
		TT	29 (25.9%)	69 (22.7%)	1.19	0.72–1.96
		C	0.518	0.512	1.03	0.75–1.39	0.03	0.87
		T	0.482	0.488	0.97	0.72–1.32